151 related articles for article (PubMed ID: 16925144)
1. The breast cancer panel: a case-based discussion on the use of targeted therapies for primary and metastatic disease.
Fortenbaugh C
ONS News; 2006; 21(8 Suppl):37-8. PubMed ID: 16925144
[No Abstract] [Full Text] [Related]
2. Expanding nursing expertise in targeted therapy.
Morse L
ONS News; 2006; 21(8 Suppl):55-6. PubMed ID: 16925153
[No Abstract] [Full Text] [Related]
3. Case-based discussion for the management of metastatic colorectal cancer.
Biedrzycki BA
ONS News; 2006; 21(8 Suppl):31-2. PubMed ID: 16925141
[No Abstract] [Full Text] [Related]
4. Adverse events in bevacizumab and chemotherapy: patient management.
Blowers E; Hall K
Br J Nurs; 2009 Apr 9-22; 18(7):424-8. PubMed ID: 19373187
[TBL] [Abstract][Full Text] [Related]
5. Review of panitumumab: a targeted therapy.
Winkeljohn DL
Clin J Oncol Nurs; 2008 Feb; 12(1):30-2. PubMed ID: 18258571
[No Abstract] [Full Text] [Related]
6. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
7. Patient-driven, evidence-based treatment for breast, lung, and prostate cancer.
King CR
ONS News; 2006; 21(8 Suppl):33-4. PubMed ID: 16925142
[No Abstract] [Full Text] [Related]
8. Advances in the treatment of multiple myeloma: a nursing perspective.
Barrick M
ONS News; 2006; 21(8 Suppl):15-6. PubMed ID: 16925133
[No Abstract] [Full Text] [Related]
9. Case studies in breast and colorectal cancer for the oncology nurse.
ONS News; 2004; 19(9 Suppl):47-8. PubMed ID: 15478584
[TBL] [Abstract][Full Text] [Related]
10. Strategies for success: optimizing oral therapies in breast and colorectal cancer.
Davies MJ
ONS News; 2006; 21(8 Suppl):7-8. PubMed ID: 16925129
[No Abstract] [Full Text] [Related]
11. Targeted therapies in breast cancer: challenging questions from oncology nurses.
Becze E
ONS Connect; 2007; 22(8 Suppl):31-2. PubMed ID: 17824554
[No Abstract] [Full Text] [Related]
12. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
13. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
14. Nanotechnology: metastatic breast cancer and beyond.
Bruce SD
ONS News; 2006; 21(8 Suppl):5-6. PubMed ID: 16925128
[No Abstract] [Full Text] [Related]
15. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
16. Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint.
Robert NJ
Breast Cancer Res Treat; 2010 Jul; 122(1):9-10. PubMed ID: 20495865
[No Abstract] [Full Text] [Related]
17. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
19. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
Montagnani F; Migali C; Fiorentini G
J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
[No Abstract] [Full Text] [Related]
20. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer.
Montemurro F; Aglietta M
Clin Breast Cancer; 2005 Apr; 6(1):77-80. PubMed ID: 15899075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
